# Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics

> **NCT06200584** · NA · COMPLETED · sponsor: **Dr Rabia Arshad** · enrollment: 140 (actual)

## Conditions studied

- Antipsychotics and Neuroleptics Toxicity

## Interventions

- **DRUG:** Risperidone
- **DRUG:** Olanzapine
- **DRUG:** Quetiapine
- **DRUG:** Risperidone and Vitamin D and Vitamin E
- **DRUG:** Olanzapine and Vitamin D and Vitamin E
- **DRUG:** Quetiapine and Vitamin D and Vitamin E

## Key facts

- **NCT ID:** NCT06200584
- **Lead sponsor:** Dr Rabia Arshad
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-06-10
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2024-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06200584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06200584, "Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06200584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*